Alginate-based Reflux Suppressant and Magnesium-aluminium Antacid Gel for Treatment of Heartburn in Pregnancy
Phase 4
Completed
- Conditions
- Heartburn in Pregnancy
- Interventions
- Drug: Alginate-based reflux suppressantDrug: magnesium-aluminium antacid gel
- Registration Number
- NCT02470117
- Lead Sponsor
- Chulalongkorn University
- Brief Summary
This study evaluates the efficacy of alginate-based reflux suppressant and magnesium-aluminium antacid gel for treatment of heartburn in pregnancy. Half of the participants will receive alginate-based reflux suppressant, while the other half will receive magnesium-aluminium antacid gel.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
- Pregnant women gestational age less than 36 weeks with heartburn
Exclusion Criteria
- Having medical disease that contraindicated to use study drug
- Allergic to alginate-based reflux suppressant and magnesium-aluminium antacid gel
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Alginate-based reflux suppressant Alginate-based reflux suppressant Alginate-based reflux suppressant 15 ml oral every 6 hours for 2 weeks magnesium-aluminium antacid gel magnesium-aluminium antacid gel magnesium-aluminium antacid gel 15 ml oral every 6 hours for 2 weeks
- Primary Outcome Measures
Name Time Method Frequency of heartburn as measured by diary chart 2 weeks
- Secondary Outcome Measures
Name Time Method Number of participants with side effects 2 weeks Intensity of hearburn as measured by visual analog scale 2 weeks quality of life as measured by questionnaire SF-8 2 weeks satisfaction as measured by questionnaire 2 weeks fetal outcomes as measured by birth weight and Apgar scores at birth
Trial Locations
- Locations (1)
Vorapong Phupong
🇹ðŸ‡Bangkok, Thailand